Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KB-436
- Development stage
- Preclinical
- Lead developer
- Kisoji Biotechnology
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KB-436 is a trispecific VHH-based antibody developed by KisoJi Biotechnology for the treatment of small cell lung cancer (SCLC) and other advanced solid tumors. It is designed to simultaneously target Dopamine Receptor 2 (DRD2), Programmed Cell Death Protein 1 (PD-1), and CD47. DRD2 is a G protein-coupled receptor often overexpressed in SCLC and associated with tumor growth and stemness. The PD-1 module aims to restore T-cell function, while the CD47 module blocks the CD47-SIRPα "don't eat me" signal and recruits T cells to the tumor microenvironment. Preclinical data indicates that KB-436 suppresses tumor growth, inhibits metastasis, and enhances the efficacy of chemotherapy.
02
Targets
CD47 (Cluster of Differentiation 47)DRD2 (Dopamine D2 Receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on KB-436.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KB-436.